Eton Pharmaceuticals (ETON) Common Equity (2017 - 2025)

Eton Pharmaceuticals has disclosed Common Equity across 9 years of filings, most recently posting $26.2 million for Q4 2025.

• Common Equity for Q4 2025 came in at $26.2 million, up 7.07% year-over-year; the trailing twelve-month figure through Dec 2025 was $26.2 million (up 7.07% YoY), and the FY2025 annual result was $26.2 million, up 7.07% from the prior year.
• Common Equity came in at $26.2 million for Q4 2025 at Eton Pharmaceuticals, up from $23.1 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $26.2 million in Q4 2025 to a low of $11.2 million in Q3 2022.
• The 5-year median for Common Equity is $16.4 million (2023), against an average of $17.7 million.
• Across the five-year window, Common Equity jumped 1028.24% in 2021 and tumbled 37.91% in 2022, its largest moves.
• Eton Pharmaceuticals' Common Equity stood at $17.6 million in 2021, then retreated by 25.82% to $13.1 million in 2022, then rose by 18.34% to $15.5 million in 2023, then soared by 57.83% to $24.4 million in 2024, then climbed by 7.07% to $26.2 million in 2025.
• The last three Common Equity figures came in at $26.2 million (Q4 2025), $23.1 million (Q3 2025), and $24.0 million (Q2 2025), per Business Quant data.